|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
18 years and older
|
|
gptkbp:allocates
|
Randomized
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:collaboratesWith
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:completedIn
|
April 2015
|
|
gptkbp:conditionStudied
|
gptkb:Type_2_Diabetes_Mellitus
|
|
gptkbp:enrollment
|
7020
|
|
gptkbp:gender
|
All
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NCT01449370
|
|
gptkbp:intervention
|
gptkb:Placebo
gptkb:Empagliflozin
|
|
gptkbp:location
|
Multinational
|
|
gptkbp:mask
|
Double
|
|
gptkbp:officialName
|
A Study of BI 10773 (Empagliflozin) in Patients With Type 2 Diabetes Mellitus at High Risk for Cardiovascular Events
|
|
gptkbp:otherIdentifier
|
EMPA-REG OUTCOME
|
|
gptkbp:primaryCompletionDate
|
April 2015
|
|
gptkbp:recognizedBy
|
gptkb:NCT01449370
|
|
gptkbp:result
|
Time to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke
|
|
gptkbp:sponsor
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:startDate
|
September 2011
|
|
gptkbp:status
|
Completed
|
|
gptkbp:studyType
|
Interventional
Randomized
Double-blind
Placebo-controlled
|
|
gptkbp:bfsParent
|
gptkb:XL518
|
|
gptkbp:bfsLayer
|
8
|